中医学报2025，Vol.40Issue(8)：1612-1621,10.DOI:10.16368/j.issn.1674-8999.2025.08.259
从瘀论治肺纤维化的现代研究进展
Modern Research Progress in Treatment of Pulmonary Fibrosis from Perspective of Stasis
摘要
Abstract
Chinese herbal prescription has shown multi-target and multi-level pharmacological effects in the treatment of pulmonary fibrosis(PF),especially in anti-inflammatory,inhibition of epithelial-mesenchymal transition(EMT)and extracellular matrix(ECM)deposition.Its main functions include regulating inflammatory factors,epithelial cell markers and Fbs markers,as well as inhibi-ting the deposition of ECM components such as Col-Ⅰ,Col-Ⅲ and HYP.Many chinese herbal prescription achieved anti-PF effects by inhibiting the TGF-β1/Smad signaling pathway.TGF-β1,as a key promoter of PF,activates a variety of downstream Smads proteins by binding to its receptors,promotes alveolar epithelium cells(AECs)injury and apoptosis,activates EMT processes,and en-hances the ECM secretion ability of Fbs.Chinese herbal prescription inhibites the development of PF at multiple levels by regulating the TGF-β1/Smad signaling pathway,and the focus of different studies was different.In addition,NF-κB is a key inflammatory regula-tor,and its signaling pathways interact with multiple signaling pathways such as MAPK/NF-κB/TGF-β1,PI3K/AKT/NF-κB and HMGB1/NF-κB forming multiple synergistic effects,which can intervene in the key pathological links of PF from multiple angles,which is manifested in significant anti-inflammatory and antioxidant effects,and at the same time inhibits the abnormal proliferation of AECs and EMT process,so as to comprehensively curb the progression of PF.关键词
肺纤维化/从瘀论治/补气化瘀法/活血化瘀法/散结消癥法Key words
pulmonary fibrosis/treatmeng from perspective of stasis/Qi-tonifying and stasis-resolving method/blood-activating and stasis-resolving method/nodule-dispersing and mass-eliminating method分类
医药卫生引用本文复制引用
余本嫚,吉郡珠,李宁,韩瑞婷,严镓文,王宇,余海滨..从瘀论治肺纤维化的现代研究进展[J].中医学报,2025,40(8):1612-1621,10.基金项目
国家重点研发计划项目(2017YFC1703506) （2017YFC1703506）
河南省"双一流"创建学科中医学科学研究专项项目(HSRP-DFCTCM-2023-3-18) （HSRP-DFCTCM-2023-3-18）
河南省中医药科学研究专项项目(2023ZXZX1033) （2023ZXZX1033）
郑州市协同创新专项项目(2023XTCX043) （2023XTCX043）
河南省中医药科学研究专项项目(2022ZYZD04) （2022ZYZD04）
